Share Price and Basic Stock Data
Last Updated: October 18, 2025, 5:18 pm
| PEG Ratio | -43.61 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Hester Biosciences Ltd, a prominent player in the pharmaceuticals industry, reported a share price of ₹1,696 and a market capitalization of ₹1,444 Cr. The company’s revenue from operations has shown a consistent upward trajectory, standing at ₹266 Cr for the year ending March 2023, compared to ₹235 Cr in March 2022. The quarterly sales data reveals fluctuations, with the highest quarterly sales of ₹88 Cr recorded in June 2023, while the lowest was ₹51 Cr in June 2022. This growth trajectory is indicative of Hester’s ability to capitalize on market opportunities, although sales experienced a dip in subsequent quarters. The operating profit margin (OPM) stood at 27%, which is relatively robust, reflecting operational efficiency. However, the cash conversion cycle (CCC) remains high at 255 days, indicating challenges in managing working capital effectively. Overall, while the revenue trends show promise, the fluctuations highlight the need for consistent performance across quarters to ensure sustainable growth.
Profitability and Efficiency Metrics
Hester Biosciences has reported a net profit of ₹29 Cr for the year ending March 2025, down from ₹39 Cr in the previous fiscal year. The earnings per share (EPS) for March 2025 stood at ₹32.31, compared to ₹46.22 in March 2022, reflecting a significant decline in profitability. The return on equity (ROE) was recorded at 9.18%, while the return on capital employed (ROCE) was slightly better at 9.71%. These profitability metrics indicate that while the company generates returns, they are below the levels typically seen in the pharmaceuticals sector, where higher returns are often expected. Furthermore, the interest coverage ratio (ICR) stood at 3.25x, suggesting that the company can comfortably meet its interest obligations. However, the declining net profit and EPS figures raise concerns about the sustainability of profitability, necessitating strategic adjustments to enhance margins and operational efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Hester Biosciences reflects a total debt of ₹213 Cr against reserves of ₹306 Cr, resulting in a debt-to-equity ratio of 0.81x. This level of leverage is indicative of a moderate risk profile, as the company maintains a reasonable balance between debt and equity financing. The current ratio is a healthy 2.03, indicating sufficient liquidity to cover short-term liabilities. Moreover, the book value per share has increased to ₹356.03, suggesting that shareholder equity is on an upward trend. However, the interest coverage ratio of 3.25x, while adequate, signals that the company is reliant on its operational income to service its debt. The decline in cash flow metrics, as evidenced by the cash conversion cycle, poses a risk to liquidity. Overall, while the balance sheet shows strength in terms of liquidity and equity, the rising borrowings and declining profitability warrant close monitoring.
Shareholding Pattern and Investor Confidence
The shareholding structure of Hester Biosciences indicates a stable promoter holding of 53.73%, which reflects strong management control and confidence in the company’s long-term vision. Foreign institutional investors (FIIs) hold a modest 0.51%, while domestic institutional investors (DIIs) account for only 0.02%, suggesting limited institutional interest. Public shareholding is significant at 45.73%, with a total of 11,810 shareholders as of March 2025. The slight decrease in the number of shareholders over recent quarters may point to some investor fatigue or concerns regarding the company’s financial performance. The consistent promoter holding can be seen as a positive indicator for investor confidence, yet the low institutional participation may limit the stock’s liquidity and potential for price discovery. In summary, while the promoter’s commitment is reassuring, the overall shareholding dynamics highlight areas for improvement in attracting institutional investors.
Outlook, Risks, and Final Insight
If Hester Biosciences can enhance its operational efficiency and stabilize its revenue streams, it may be positioned to improve its profitability metrics. The declining net profit and EPS figures necessitate a strategic focus on cost management and innovation to regain investor confidence and enhance market positioning. Risks include the high cash conversion cycle, which could strain liquidity, and the reliance on operational income to service debt, potentially impacting financial stability. Furthermore, the lack of institutional interest may hinder the stock’s performance in a competitive market. To navigate these challenges, the company may need to address its working capital management while exploring avenues for growth, such as expanding its product portfolio or entering new markets. A balanced approach to managing risks and leveraging strengths will be crucial for Hester to achieve sustainable growth in the evolving pharmaceuticals landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Hester Biosciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 117 | 247/84.3 | 33.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,702 Cr. | 432 | 440/192 | 105 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.4 Cr. | 49.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.0 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,828.94 Cr | 1,185.68 | 50.47 | 194.07 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 73 | 75 | 67 | 88 | 70 | 67 | 79 | 82 | 84 | 63 | 82 | 84 |
| Expenses | 43 | 60 | 56 | 56 | 73 | 57 | 57 | 63 | 65 | 65 | 58 | 63 | 61 |
| Operating Profit | 7 | 13 | 19 | 12 | 14 | 13 | 10 | 16 | 18 | 19 | 5 | 19 | 23 |
| OPM % | 15% | 17% | 25% | 17% | 16% | 19% | 15% | 20% | 21% | 23% | 8% | 23% | 27% |
| Other Income | 5 | 5 | 6 | 3 | 3 | 6 | 2 | 5 | 2 | 3 | 9 | -6 | 3 |
| Interest | 2 | 2 | 4 | 1 | 3 | 8 | 2 | 7 | 5 | 6 | -4 | 6 | 2 |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Profit before tax | 5 | 10 | 16 | 8 | 9 | 7 | 6 | 10 | 11 | 12 | 13 | 4 | 20 |
| Tax % | 35% | 36% | 24% | 32% | 25% | 40% | 37% | 35% | 29% | 29% | 15% | 59% | 14% |
| Net Profit | 4 | 7 | 12 | 6 | 7 | 4 | 4 | 6 | 7 | 8 | 11 | 2 | 17 |
| EPS in Rs | 4.67 | 8.16 | 13.15 | 5.33 | 6.90 | 4.81 | 4.68 | 5.82 | 7.45 | 9.64 | 13.71 | 1.52 | 19.33 |
Last Updated: August 1, 2025, 8:05 pm
Below is a detailed analysis of the quarterly data for Hester Biosciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 84.00 Cr.. The value appears strong and on an upward trend. It has increased from 82.00 Cr. (Mar 2025) to 84.00 Cr., marking an increase of 2.00 Cr..
- For Expenses, as of Jun 2025, the value is 61.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 63.00 Cr. (Mar 2025) to 61.00 Cr., marking a decrease of 2.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 23.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 4.00 Cr..
- For OPM %, as of Jun 2025, the value is 27.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Mar 2025) to 27.00%, marking an increase of 4.00%.
- For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from -6.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 9.00 Cr..
- For Interest, as of Jun 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 16.00 Cr..
- For Tax %, as of Jun 2025, the value is 14.00%. The value appears to be improving (decreasing) as expected. It has decreased from 59.00% (Mar 2025) to 14.00%, marking a decrease of 45.00%.
- For Net Profit, as of Jun 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 15.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 19.33. The value appears strong and on an upward trend. It has increased from 1.52 (Mar 2025) to 19.33, marking an increase of 17.81.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:13 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69 | 90 | 101 | 123 | 136 | 178 | 183 | 214 | 235 | 266 | 305 | 311 | 313 |
| Expenses | 44 | 64 | 67 | 82 | 89 | 110 | 128 | 146 | 175 | 215 | 251 | 250 | 247 |
| Operating Profit | 24 | 25 | 34 | 41 | 47 | 68 | 55 | 69 | 60 | 51 | 54 | 62 | 66 |
| OPM % | 36% | 28% | 34% | 33% | 35% | 38% | 30% | 32% | 26% | 19% | 18% | 20% | 21% |
| Other Income | 1 | 3 | 1 | 0 | 3 | 7 | 6 | 1 | 14 | 20 | 15 | 8 | 9 |
| Interest | 6 | 5 | 4 | 4 | 4 | 7 | 7 | 7 | 4 | 9 | 20 | 13 | 10 |
| Depreciation | 5 | 6 | 6 | 7 | 10 | 12 | 13 | 13 | 17 | 21 | 17 | 17 | 17 |
| Profit before tax | 13 | 18 | 25 | 31 | 36 | 57 | 41 | 50 | 54 | 40 | 32 | 40 | 49 |
| Tax % | 31% | 26% | 23% | 26% | 36% | 28% | 25% | 31% | 26% | 30% | 34% | 27% | |
| Net Profit | 9 | 13 | 19 | 23 | 23 | 41 | 31 | 35 | 39 | 28 | 21 | 29 | 39 |
| EPS in Rs | 11.11 | 15.99 | 22.57 | 27.68 | 30.12 | 48.87 | 34.29 | 40.47 | 46.22 | 31.30 | 22.21 | 32.31 | 44.20 |
| Dividend Payout % | 18% | 19% | 18% | 19% | 33% | 23% | 19% | 25% | 22% | 26% | 27% | 22% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 44.44% | 46.15% | 21.05% | 0.00% | 78.26% | -24.39% | 12.90% | 11.43% | -28.21% | -25.00% | 38.10% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1.71% | -25.10% | -21.05% | 78.26% | -102.65% | 37.29% | -1.47% | -39.63% | 3.21% | 63.10% |
Hester Biosciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 11% |
| 3 Years: | 10% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -1% |
| 3 Years: | -11% |
| TTM: | 94% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 6% |
| 3 Years: | 0% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| Last Year: | 9% |
Last Updated: September 5, 2025, 6:05 am
Balance Sheet
Last Updated: July 25, 2025, 3:06 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 66 | 76 | 93 | 113 | 132 | 169 | 193 | 220 | 251 | 271 | 283 | 306 |
| Borrowings | 48 | 55 | 59 | 66 | 69 | 90 | 121 | 110 | 228 | 274 | 244 | 213 |
| Other Liabilities | 19 | 20 | 25 | 25 | 35 | 32 | 65 | 73 | 74 | 116 | 126 | 126 |
| Total Liabilities | 142 | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 |
| Fixed Assets | 54 | 60 | 65 | 102 | 110 | 145 | 142 | 133 | 237 | 259 | 240 | 233 |
| CWIP | 21 | 33 | 36 | 21 | 32 | 7 | 74 | 109 | 82 | 149 | 171 | 183 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 25 | 30 | 34 |
| Other Assets | 68 | 68 | 85 | 89 | 102 | 148 | 170 | 169 | 222 | 237 | 221 | 203 |
| Total Assets | 142 | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | 670 | 662 | 653 |
Below is a detailed analysis of the balance sheet data for Hester Biosciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
- For Reserves, as of Mar 2025, the value is 306.00 Cr.. The value appears strong and on an upward trend. It has increased from 283.00 Cr. (Mar 2024) to 306.00 Cr., marking an increase of 23.00 Cr..
- For Borrowings, as of Mar 2025, the value is 213.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 244.00 Cr. (Mar 2024) to 213.00 Cr., marking a decrease of 31.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 126.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 126.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 653.00 Cr.. The value appears to be improving (decreasing). It has decreased from 662.00 Cr. (Mar 2024) to 653.00 Cr., marking a decrease of 9.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 233.00 Cr.. The value appears to be declining and may need further review. It has decreased from 240.00 Cr. (Mar 2024) to 233.00 Cr., marking a decrease of 7.00 Cr..
- For CWIP, as of Mar 2025, the value is 183.00 Cr.. The value appears strong and on an upward trend. It has increased from 171.00 Cr. (Mar 2024) to 183.00 Cr., marking an increase of 12.00 Cr..
- For Investments, as of Mar 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 30.00 Cr. (Mar 2024) to 34.00 Cr., marking an increase of 4.00 Cr..
- For Other Assets, as of Mar 2025, the value is 203.00 Cr.. The value appears to be declining and may need further review. It has decreased from 221.00 Cr. (Mar 2024) to 203.00 Cr., marking a decrease of 18.00 Cr..
- For Total Assets, as of Mar 2025, the value is 653.00 Cr.. The value appears to be declining and may need further review. It has decreased from 662.00 Cr. (Mar 2024) to 653.00 Cr., marking a decrease of 9.00 Cr..
Notably, the Reserves (306.00 Cr.) exceed the Borrowings (213.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -24.00 | -30.00 | -25.00 | -25.00 | -22.00 | -22.00 | -66.00 | -41.00 | -168.00 | -223.00 | -190.00 | -151.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 72 | 95 | 79 | 87 | 67 | 116 | 84 | 86 | 109 | 94 | 86 |
| Inventory Days | 1,145 | 431 | 627 | 376 | 505 | 540 | 834 | 452 | 424 | 399 | 288 | 291 |
| Days Payable | 145 | 68 | 109 | 84 | 100 | 93 | 261 | 204 | 101 | 141 | 98 | 122 |
| Cash Conversion Cycle | 1,074 | 434 | 614 | 371 | 491 | 514 | 690 | 332 | 409 | 367 | 284 | 255 |
| Working Capital Days | 36 | 76 | 112 | 90 | 82 | 106 | 104 | 134 | 113 | 88 | 112 | 74 |
| ROCE % | 18% | 15% | 19% | 19% | 20% | 26% | 16% | 18% | 14% | 9% | 9% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 41 | 0.08 | 0.01 | 41 | 2025-04-22 17:25:33 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 33.89 | 24.88 | 32.96 | 46.41 | 40.79 |
| Diluted EPS (Rs.) | 33.89 | 24.88 | 32.96 | 46.41 | 40.79 |
| Cash EPS (Rs.) | 48.82 | 39.65 | 52.10 | 65.41 | 56.44 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 369.41 | 356.03 | 339.19 | 314.32 | 277.37 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 369.41 | 356.03 | 339.19 | 314.32 | 277.37 |
| Revenue From Operations / Share (Rs.) | 365.70 | 357.99 | 312.79 | 276.25 | 251.95 |
| PBDIT / Share (Rs.) | 76.38 | 75.58 | 77.30 | 86.66 | 86.21 |
| PBIT / Share (Rs.) | 56.63 | 55.39 | 52.97 | 67.17 | 70.56 |
| PBT / Share (Rs.) | 41.70 | 32.14 | 42.02 | 62.39 | 58.90 |
| Net Profit / Share (Rs.) | 29.07 | 19.46 | 27.77 | 45.92 | 40.79 |
| NP After MI And SOA / Share (Rs.) | 32.31 | 22.20 | 31.30 | 46.41 | 40.47 |
| PBDIT Margin (%) | 20.88 | 21.11 | 24.71 | 31.37 | 34.21 |
| PBIT Margin (%) | 15.48 | 15.47 | 16.93 | 24.31 | 28.00 |
| PBT Margin (%) | 11.40 | 8.97 | 13.43 | 22.58 | 23.37 |
| Net Profit Margin (%) | 7.94 | 5.43 | 8.87 | 16.62 | 16.18 |
| NP After MI And SOA Margin (%) | 8.83 | 6.20 | 10.00 | 16.80 | 16.06 |
| Return on Networth / Equity (%) | 8.74 | 6.47 | 9.51 | 15.18 | 15.08 |
| Return on Capital Employeed (%) | 9.12 | 8.46 | 8.64 | 12.28 | 17.16 |
| Return On Assets (%) | 4.20 | 2.85 | 3.97 | 7.02 | 8.37 |
| Long Term Debt / Equity (X) | 0.42 | 0.62 | 0.66 | 0.63 | 0.36 |
| Total Debt / Equity (X) | 0.66 | 0.81 | 0.95 | 0.85 | 0.37 |
| Asset Turnover Ratio (%) | 0.47 | 0.45 | 0.43 | 0.52 | 0.62 |
| Current Ratio (X) | 1.56 | 2.03 | 1.53 | 2.01 | 2.63 |
| Quick Ratio (X) | 0.99 | 1.31 | 0.96 | 1.23 | 1.62 |
| Inventory Turnover Ratio (X) | 4.26 | 0.67 | 0.66 | 0.52 | 0.39 |
| Dividend Payout Ratio (NP) (%) | 18.56 | 36.02 | 31.94 | 21.54 | 16.30 |
| Dividend Payout Ratio (CP) (%) | 11.52 | 18.86 | 17.97 | 15.17 | 11.76 |
| Earning Retention Ratio (%) | 81.44 | 63.98 | 68.06 | 78.46 | 83.70 |
| Cash Earning Retention Ratio (%) | 88.48 | 81.14 | 82.03 | 84.83 | 88.24 |
| Interest Coverage Ratio (X) | 5.12 | 3.25 | 7.06 | 18.14 | 11.11 |
| Interest Coverage Ratio (Post Tax) (X) | 2.95 | 1.84 | 3.53 | 10.61 | 6.76 |
| Enterprise Value (Cr.) | 1279.65 | 1416.65 | 1555.60 | 2514.68 | 1703.08 |
| EV / Net Operating Revenue (X) | 4.11 | 4.65 | 5.85 | 10.70 | 7.95 |
| EV / EBITDA (X) | 19.69 | 22.03 | 23.66 | 34.11 | 23.22 |
| MarketCap / Net Operating Revenue (X) | 3.43 | 3.88 | 4.86 | 9.83 | 7.61 |
| Retention Ratios (%) | 81.43 | 63.97 | 68.05 | 78.45 | 83.69 |
| Price / BV (X) | 3.39 | 4.05 | 4.62 | 8.88 | 7.14 |
| Price / Net Operating Revenue (X) | 3.43 | 3.88 | 4.86 | 9.83 | 7.61 |
| EarningsYield | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 |
After reviewing the key financial ratios for Hester Biosciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 33.89. This value is within the healthy range. It has increased from 24.88 (Mar 24) to 33.89, marking an increase of 9.01.
- For Diluted EPS (Rs.), as of Mar 25, the value is 33.89. This value is within the healthy range. It has increased from 24.88 (Mar 24) to 33.89, marking an increase of 9.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 48.82. This value is within the healthy range. It has increased from 39.65 (Mar 24) to 48.82, marking an increase of 9.17.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 369.41. It has increased from 356.03 (Mar 24) to 369.41, marking an increase of 13.38.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 369.41. It has increased from 356.03 (Mar 24) to 369.41, marking an increase of 13.38.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 365.70. It has increased from 357.99 (Mar 24) to 365.70, marking an increase of 7.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 76.38. This value is within the healthy range. It has increased from 75.58 (Mar 24) to 76.38, marking an increase of 0.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is 56.63. This value is within the healthy range. It has increased from 55.39 (Mar 24) to 56.63, marking an increase of 1.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 41.70. This value is within the healthy range. It has increased from 32.14 (Mar 24) to 41.70, marking an increase of 9.56.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 29.07. This value is within the healthy range. It has increased from 19.46 (Mar 24) to 29.07, marking an increase of 9.61.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 32.31. This value is within the healthy range. It has increased from 22.20 (Mar 24) to 32.31, marking an increase of 10.11.
- For PBDIT Margin (%), as of Mar 25, the value is 20.88. This value is within the healthy range. It has decreased from 21.11 (Mar 24) to 20.88, marking a decrease of 0.23.
- For PBIT Margin (%), as of Mar 25, the value is 15.48. This value is within the healthy range. It has increased from 15.47 (Mar 24) to 15.48, marking an increase of 0.01.
- For PBT Margin (%), as of Mar 25, the value is 11.40. This value is within the healthy range. It has increased from 8.97 (Mar 24) to 11.40, marking an increase of 2.43.
- For Net Profit Margin (%), as of Mar 25, the value is 7.94. This value is within the healthy range. It has increased from 5.43 (Mar 24) to 7.94, marking an increase of 2.51.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.83. This value is within the healthy range. It has increased from 6.20 (Mar 24) to 8.83, marking an increase of 2.63.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.74. This value is below the healthy minimum of 15. It has increased from 6.47 (Mar 24) to 8.74, marking an increase of 2.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.12. This value is below the healthy minimum of 10. It has increased from 8.46 (Mar 24) to 9.12, marking an increase of 0.66.
- For Return On Assets (%), as of Mar 25, the value is 4.20. This value is below the healthy minimum of 5. It has increased from 2.85 (Mar 24) to 4.20, marking an increase of 1.35.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.42, marking a decrease of 0.20.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.66. This value is within the healthy range. It has decreased from 0.81 (Mar 24) to 0.66, marking a decrease of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.47. It has increased from 0.45 (Mar 24) to 0.47, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.56, marking a decrease of 0.47.
- For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has decreased from 1.31 (Mar 24) to 0.99, marking a decrease of 0.32.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.26. This value is within the healthy range. It has increased from 0.67 (Mar 24) to 4.26, marking an increase of 3.59.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 18.56. This value is below the healthy minimum of 20. It has decreased from 36.02 (Mar 24) to 18.56, marking a decrease of 17.46.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.52. This value is below the healthy minimum of 20. It has decreased from 18.86 (Mar 24) to 11.52, marking a decrease of 7.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 81.44. This value exceeds the healthy maximum of 70. It has increased from 63.98 (Mar 24) to 81.44, marking an increase of 17.46.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.48. This value exceeds the healthy maximum of 70. It has increased from 81.14 (Mar 24) to 88.48, marking an increase of 7.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.12. This value is within the healthy range. It has increased from 3.25 (Mar 24) to 5.12, marking an increase of 1.87.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 3. It has increased from 1.84 (Mar 24) to 2.95, marking an increase of 1.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,279.65. It has decreased from 1,416.65 (Mar 24) to 1,279.65, marking a decrease of 137.00.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.11. This value exceeds the healthy maximum of 3. It has decreased from 4.65 (Mar 24) to 4.11, marking a decrease of 0.54.
- For EV / EBITDA (X), as of Mar 25, the value is 19.69. This value exceeds the healthy maximum of 15. It has decreased from 22.03 (Mar 24) to 19.69, marking a decrease of 2.34.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has decreased from 3.88 (Mar 24) to 3.43, marking a decrease of 0.45.
- For Retention Ratios (%), as of Mar 25, the value is 81.43. This value exceeds the healthy maximum of 70. It has increased from 63.97 (Mar 24) to 81.43, marking an increase of 17.46.
- For Price / BV (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has decreased from 4.05 (Mar 24) to 3.39, marking a decrease of 0.66.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has decreased from 3.88 (Mar 24) to 3.43, marking a decrease of 0.45.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hester Biosciences Ltd:
- Net Profit Margin: 7.94%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.12% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.74% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.95
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.99
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 38.8 (Industry average Stock P/E: 50.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.66
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.94%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | �Pushpak� 1st Floor, Panchvati Circle, Ahmedabad Gujarat 380006 | mail@hester.in http://www.hester.in |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Bhupendra Gandhi | Chairman |
| Mr. Rajiv Gandhi | Managing Director & CEO |
| Ms. Priya Gandhi | Executive Director |
| Mr. Ravin Gandhi | Director |
| Mr. Sanjiv Gandhi | Director |
| Mr. Ashok Bhadakal | Independent Director |
| Ms. Sandhya Patel | Independent Director |
| Mr. Ameet Desai | Independent Director |
| Mr. Anil Jain | Independent Director |
| Mr. Jatin Trivedi | Independent Director |
| Ms. Nina Gandhi | Alternate Director |
FAQ
What is the intrinsic value of Hester Biosciences Ltd?
Hester Biosciences Ltd's intrinsic value (as of 18 October 2025) is 1055.77 which is 38.40% lower the current market price of 1,714.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,458 Cr. market cap, FY2025-2026 high/low of 2,786/1,243, reserves of ₹306 Cr, and liabilities of 653 Cr.
What is the Market Cap of Hester Biosciences Ltd?
The Market Cap of Hester Biosciences Ltd is 1,458 Cr..
What is the current Stock Price of Hester Biosciences Ltd as on 18 October 2025?
The current stock price of Hester Biosciences Ltd as on 18 October 2025 is 1,714.
What is the High / Low of Hester Biosciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hester Biosciences Ltd stocks is 2,786/1,243.
What is the Stock P/E of Hester Biosciences Ltd?
The Stock P/E of Hester Biosciences Ltd is 38.8.
What is the Book Value of Hester Biosciences Ltd?
The Book Value of Hester Biosciences Ltd is 369.
What is the Dividend Yield of Hester Biosciences Ltd?
The Dividend Yield of Hester Biosciences Ltd is 0.41 %.
What is the ROCE of Hester Biosciences Ltd?
The ROCE of Hester Biosciences Ltd is 9.71 %.
What is the ROE of Hester Biosciences Ltd?
The ROE of Hester Biosciences Ltd is 9.18 %.
What is the Face Value of Hester Biosciences Ltd?
The Face Value of Hester Biosciences Ltd is 10.0.